Short answer
Sionna Therapeutics, Inc. (SION) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Press release covers Sionna Therapeutics’ quarter ended June 30, 2026.
Sionna Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Press release covers Sionna Therapeutics’ quarter ended June 30, 2026
- Financial results and business highlights available in Exhibit 99.1
- Investor focus: quarterly cash position, clinical progress and development outlook in the attached release
Item EX-99.1 · Exhibit EX-99.1
- Q2 2026 net loss $29.9M, widening from $18.1M; loss per share $0.66 versus $0.41
- R&D spending $21.9M, up from $15.4M, reflecting accelerated clinical pipeline investment
- Cash, equivalents and marketable securities $268.3M, expected to fund operations into 2028
- Topline data expected summer 2026 for SION-719 Phase 2a and SION-451 Phase 1 combination trials
- Six-month net loss $56.7M versus $34.6M, signaling rising cash consumption despite extended runway
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Sionna Therapeutics, Inc. 8-K filings
Get the next SION 8-K as it lands
Follow SION for push alerts, or ask the research agent what this filing means.